Resonance Health Ltd (AU:RHT)
ASX:RHT
Top Page
Resonance Health Ltd
(Sydney:RHT)
Select Model
Select Model
Rating:47Neutral
Price Target:
AU$0.04
▼(-26.00% Downside)
Action:ReiteratedDate:03/03/26
The score is primarily held back by weak financial performance—ongoing losses and a sharp decline in free cash flow—despite a relatively stable balance sheet. Technicals also lean negative with the stock trading below major moving averages. Valuation is only moderately supportive given a P/E of 23.75 and no dividend yield.
Positive Factors
Balance sheet strength
A moderate debt-to-equity (0.40) and a 52.5% equity ratio indicate a solid capital structure that reduces leverage-driven stress. This provides financial resilience and flexibility over the next 2–6 months to fund operations or absorb shocks without immediate refinancing pressure.
Negative Factors
Sharp free cash flow decline
A 66.54% drop in free cash flow materially reduces internal funds available for investment, clinical validation, or sales expansion. Over 2–6 months this constrains strategic initiatives and may force reliance on external financing, diluting optionality and increasing execution risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet strength
A moderate debt-to-equity (0.40) and a 52.5% equity ratio indicate a solid capital structure that reduces leverage-driven stress. This provides financial resilience and flexibility over the next 2–6 months to fund operations or absorb shocks without immediate refinancing pressure.
Read all positive factors
Resonance Health Ltd (RHT) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$19.08M
Dividend YieldN/A
Average Volume (3M)274.25K
Price to Earnings (P/E)4.0
Beta (1Y)1.59
Revenue Growth28.91%
EPS Growth-1050.00%
CountryAU
Employees18
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)<0.01
Shares Outstanding477,120,240
10 Day Avg. Volume456,299
30 Day Avg. Volume274,246
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.89
Price to Sales (P/S)1.60
P/FCF Ratio22.05
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Resonance Health Ltd Business Overview & Revenue Model
Company Description
Resonance Health Limited, a healthcare technology and services company, designs, develops, and manufactures software-as-medical devices in the Asia Pacific, North America, South America, Europe, the Middle East, and Africa. It offers FerriScan, a ...
How the Company Makes Money
Resonance Health generates revenue primarily through the sale of its software products and diagnostic services to healthcare providers and institutions. The company charges fees for its advanced imaging analysis services, which are often integrate...
Resonance Health Ltd Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
55
Neutral
Cash Flow
40
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 13.84M | 11.07M | 8.59M | 4.40M | 3.83M | 3.78M |
| Gross Profit | 13.36M | 11.07M | 8.59M | 4.40M | 3.83M | 3.78M |
| EBITDA | 1.38M | -1.41M | -382.00K | -827.69K | -1.34M | 707.69K |
| Net Income | 769.30K | -1.73M | 169.30K | -780.00K | -1.14M | 585.86K |
Balance Sheet | ||||||
| Total Assets | 17.96M | 17.89M | 20.28M | 10.98M | 11.69M | 12.44M |
| Cash, Cash Equivalents and Short-Term Investments | 2.69M | 2.98M | 6.85M | 6.36M | 6.78M | 8.86M |
| Total Debt | 5.20M | 3.80M | 3.70M | 272.94K | 268.22K | 60.10K |
| Total Liabilities | 7.02M | 8.50M | 9.35M | 1.05M | 995.58K | 611.74K |
| Stockholders Equity | 10.94M | 9.39M | 10.93M | 9.94M | 10.69M | 11.83M |
Cash Flow | ||||||
| Free Cash Flow | 46.91K | 805.39K | 1.01M | -624.93K | -1.42M | 772.72K |
| Operating Cash Flow | 420.56K | 1.25M | 1.39M | -157.03K | -712.67K | 1.17M |
| Investing Cash Flow | -551.51K | -4.52M | -3.94M | -467.90K | -704.00K | -395.79K |
| Financing Cash Flow | -624.12K | -649.26K | 3.01M | -81.97K | -107.11K | 1.20M |
Resonance Health Ltd Technical Analysis
Negative
0.05
Price Trends
0.04
Negative
0.05
Negative
0.04
Negative
Market Momentum
>-0.01
Negative
45.27
Neutral
12.50
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:RHT, the sentiment is Negative. The current price of 0.05 is above the 20-day moving average (MA) of 0.04, above the 50-day MA of 0.04, and above the 200-day MA of 0.04, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 45.27 is Neutral, neither overbought nor oversold. The STOCH value of 12.50 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:RHT.
Resonance Health Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$20.00M | -7.11 | -19.01% | ― | 6.77% | -8.45% | |
47 Neutral | AU$19.08M | 3.95 | 7.57% | ― | 28.91% | -1050.00% | |
43 Neutral | AU$63.14M | -6.64 | -59.96% | ― | ― | ― | |
43 Neutral | AU$38.71M | -4.21 | -52.26% | ― | -36.68% | 79.41% | |
42 Neutral | AU$36.58M | -3.13 | -1009.84% | ― | 25.98% | 22.10% | |
41 Neutral | AU$10.13M | -0.96 | 152.58% | ― | -40.05% | -49.57% |
* Healthcare Sector Average
AU:RHT
Resonance Health Ltd
0.04
<0.01
5.26%
AU:SHG
Singular Health Group Ltd
0.20
-0.04
-16.67%
AU:IME
ImExHS Limited
0.37
-0.02
-5.13%
AU:EMD
Emyria Ltd
0.05
0.02
50.00%
AU:HIQ
HitIQ Limited
0.02
-0.02
-57.89%
AU:PCK
PainChek Ltd
0.18
-0.15
-46.81%
Resonance Health Ltd Corporate Events
Resonance Health Boosts Cash Reserves With $733k R&D Tax Refund
Mar 16, 2026
Resonance Health Ltd has received a net cash refund of $732,851 from the Australian Taxation Office, representing the balance of its FY2025 research and development tax incentive of $832,959 after offsetting $100,108 in income tax payable. The ref...
Resonance Health Seeks ASX Quotation for New Employee Incentive Shares
Mar 1, 2026
Resonance Health Ltd has applied to the ASX for quotation of 2,327,586 new ordinary fully paid shares issued on 27 February 2026. The new shares were issued under an employee incentive scheme and will be quoted on the market, indicating continued ...
Resonance Health Swings to Profit on Strong Revenue Growth and Pipeline Gains
Feb 27, 2026
Resonance Health reported a strong first half of FY26, with revenue rising 53% to $8.0 million and normalised EBITDA reaching $1.6 million at a 20% operating margin, turning a prior-year loss into a $1.5 million profit after tax and delivering pos...
Resonance Health posts record half-year revenue and returns to profit
Feb 27, 2026
Resonance Health reported a 53% jump in half-year revenue to $8 million and returned to profitability with a $1.5 million net profit after tax, supported by positive operating cash flow and a 20% normalised EBITDA margin. Growth was driven across ...
Resonance Health Delivers Strong Quarter as Trials, SaMD Pipeline and Clinics Expand
Jan 30, 2026
Resonance Health reported strong operational and financial momentum for the quarter ended 31 December 2025, with customer receipts of $2.9 million, positive operating cash flow and unaudited first-half FY26 revenue of $8.0 million, supported by hi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.